MRC Technology and Boston University Collaborate to Develop Anti-IL-16 Antibody for Treatment of Inflammatory Conditions
Published: Oct 10, 2013
London, UK, 10 October 2013: MRC Technology, a technology transfer organisation, announced today it is collaborating with Boston University to develop an anti-IL-16 antibody for use in treatment of inflammatory diseases and Ischaemic Reperfusion Injury (IRI). The project is funded in part through a Biomedical Catalyst award of £577,000, granted to MRC Technology in 2012.
The antibody has potential in a range of inflammatory diseases, such as Crohn's Disease, Lupus, asthma, as well as in IRI. IRI is the tissue damage and ensuing inflammatory response resulting from a sudden loss of blood flow, such as may occur during surgery or as a result of a blood clot. This can result in poor clinical outcomes and extended hospital stays for patients, and a large healthcare burden.
The antibody was developed by Boston University and humanized by MRC Technology. The MRC Technology team will now perform further engineering, as well as detailed x-ray structural analysis to understand more about the functionality of IL-16. Boston University will test and validate the antibody both in vivo and in vitro.
Professor Justin Bryans, Director of Drug Discovery at MRC Technology said: “The general anti-inflammatory field is a large market, and IL-16 has the potential to cover a broad range of indications. We are very pleased that Boston University chose to work with MRC Technology.”
“MRC Technology has been very supportive and a real pleasure to work with. The group’s scientists were able to humanize the antibody very efficiently, and we are in the process of characterizing its efficacy in vitro and in vivo.” Commented Bill Cruikshank, Professor of Medicine at Boston University. “We look forward to collaborating further on this project.”
Phone: +44 (0) 7771 730919
At MRC Technology
Marketing & Communications Officer
Phone: +44 (0)20 7391 2798
About MRC Technology
MRC Technology (www.mrctechnology.org) is an independent life science technology transfer charity, offering professional services to organisations within the academic, charity, biotechnology and pharmaceutical sectors globally. Services include IP management and research and development for diagnostics, small molecules and therapeutic antibodies. MRC Technology bridges the gap between basic medical research and commercialisation, helping early discoveries progress to clinical application.
About Boston University
Founded in 1839, Boston University is an internationally recognized institution of higher education and research. With more than 33,000 students, it is the fourth-largest independent university in the United States. BU consists of 16 schools and colleges, along with a number of multi-disciplinary centers and institutes integral to the University’s research and teaching mission. In 2012, BU joined the Association of American Universities (AAU), a consortium of 62 leading research universities in the United States and Canada.
Help employers find you! Check out all the jobs and post your resume.